The median overall survival of patients with MPN/CMML, JAK2-mutated CMML, JAK2-nonmutated CMML, and PV without a CMML phenotype was 27, 28, 29, and 186 months, respectively. This evidence concerns the gene JAK2 and myeloproliferative disorder.